Senior Mass Spec Scientist, tLNP Analytics

ABBVIE; North Chicago (IL); On-site; USD 97,000 - 184,000; Full time

Job summary

AbbVie seeks a Senior Scientist I in Analytical Development for Mass Spectrometry in the tLNP CMC team. You will develop LC-MS methods to characterize biotherapeutics, including mRNA and oligonucleotides, supporting drug substance and product development.

The role emphasizes hands-on method development and cross-functional collaboration. You will document results, mentor teammates, and help draft regulatory submissions while advancing analytical capabilities for state-of-the-art tLNP medicines.

Qualifications

• Ph.D. in Analytical Chemistry, Biochemistry, or related field with relevant industry experience.
• Hands-on LC-MS method development for biotherapeutics and LNP analysis preferred.
• Strong documentation and collaboration skills within cross-functional teams.

Responsibilities

• Operate and troubleshoot MS (Orbitrap/TOF) and LC platforms; maintain instruments.
• Develop LC-MS methods to characterize mRNA, oligonucleotides, antibodies, and LNPs.
• Document procedures and results in ELN; contribute to regulatory submissions.
• Collaborate with Discovery, Process Chemistry, and QA to advance programs.
• Advance LC-MS techniques to improve efficiency and analytical toolbox.

Skills

Mass spectrometry

LC-MS

Analytical method development

Biotherapeutics

Data analysis

Education

Ph.D. in Analytical Chemistry, Biochemistry, Pharmaceutical Sciences, or closely related field

Tools

XCalibur

MassLynx

Skyline

FreeStyle

Protein Metrics

BioPharma Finder

Job description

AbbVie seeks a Senior Scientist I in Analytical Development for Mass Spectrometry in the tLNP CMC team. You will develop LC-MS methods to characterize biotherapeutics, including mRNA and oligonucleotides, supporting drug substance and product development.

The role emphasizes hands-on method development and cross-functional collaboration. You will document results, mentor teammates, and help draft regulatory submissions while advancing analytical capabilities for state-of-the-art tLNP medicines.